Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination of lignan compound and furocoumarin compound to treatment of liver fibrosis

A furanocoumarin and liver fibrosis technology, which is applied in the fields of biomedicine and medicine to achieve the effect of reliable curative effect and clear mechanism

Active Publication Date: 2020-12-22
THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no internationally recognized drug that is safe, effective, liver-targeted, and long-term tolerated by the FDA for the treatment of human liver fibrosis.
At the same time, the treatment of liver fibrosis still has no chemical drugs that have entered clinical application, but is limited to controlling the etiology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of lignan compound and furocoumarin compound to treatment of liver fibrosis
  • Application of combination of lignan compound and furocoumarin compound to treatment of liver fibrosis
  • Application of combination of lignan compound and furocoumarin compound to treatment of liver fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0073] 1. Schisandra Alcohol B / Wedelolide Treating BDL-Induced Hepatic Fibrosis Model Mice

[0074] C57BL / 6 mice were adaptively fed for one week, and fasted without water the day before the operation. Receive surgical instruments in the disinfection supply room. The state of the mice was observed before the operation, and the mice in good condition were anesthetized with barbital sodium and their abdomen was depilated. The mice were placed in a supine position, fixed on the operating table, and the surgical field of view was sterilized. The opening was positioned at the xiphoid process of the mouse chest, the midline skin of the abdomen was lifted slightly, the abdomen was opened layer by layer, the muscles on both sides of the abdomen were fixed, and then pulled outward slightly to expose the abdominal view, and the intestinal tube was covered with sterile wet gauze. Use a wet cotton swab to turn up the lower edge of the liver to find the duodenal ligament and gently pull ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of combination of a lignan compound and a furocoumarin compound to reduction of expression of any one or more of transforming growth factor-[beta]1, platelet-derived growth factor and vascular endothelial cell growth factor mRNA. The combination of the lignan compound and the furocoumarin compound remarkably reduces the liver fibrosis degree of mice in a BDLmodel and a CCl4 model.

Description

technical field [0001] The application relates to the fields of biomedicine and medicine, in particular to the application of lignan compounds combined with furanocoumarin compounds in the treatment of liver fibrosis. Background technique [0002] Liver disease is a major health problem worldwide. If left untreated, it may develop into cirrhosis, portal hypertension, hepatic encephalopathy and even lead to liver failure and death. Hepatic fibrosis (Hepatic fibrosis, HF) is a variety of chronic liver diseases (including chronic viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver, autoimmune liver disease, metabolic liver disease, parasitic liver disease, toxic liver disease and Drug-induced liver injury) common pathological basis, accounting for 50% of the mortality of patients with liver cancer, liver failure and cirrhosis and other liver failure diseases, due to chemical toxicity, serum alanine transferase and aspartate aminotransferase Increased levels are...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/36A61K31/37A61P1/16
CPCA61K31/36A61K31/37A61P1/16A61K2300/00
Inventor 柏兆方肖小河艾永强左晓彬孙小茗
Owner THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com